COMMUNIQUÉS West-GlobeNewswire

-
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
18/09/2025 -
EssilorLuxottica: Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur
18/09/2025 -
EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future
18/09/2025 -
Fangzhou Named ‘Outstanding Growth Story in Hong Kong Stocks’ at China Capital Market Development Forum 2025
18/09/2025 -
Aurora Spine Announces Launch of its DEXA-L™ Anterior Lumbar Interbody Fusion Device
18/09/2025 -
Are Women on the Frontline of Antimicrobial Resistance?
17/09/2025 -
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
17/09/2025 -
Vaxart Appoints W. Mark Watson as Lead Independent Director
17/09/2025 -
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
17/09/2025 -
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
17/09/2025 -
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
17/09/2025 -
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
17/09/2025 -
CooperCompanies Announces Expanded Share Repurchase Program
17/09/2025 -
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
17/09/2025 -
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
17/09/2025 -
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
17/09/2025 -
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
17/09/2025 -
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
17/09/2025 -
Esteworld Concludes Four-Day Consultation Series at Covent Garden, London
17/09/2025
Pages